Pharvaris shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416 (deucrictibant immediate-release capsules) for the on-demand treatment of HAE attacks, including data focused on time-to-symptom relief and resolution of HAE attacks, in two poster presentations at the 2023 U.S. Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida from 20-23 July 2023.

The two presentations were:

  • Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial. Presenter: Dr. Marc A. Riedl
  • Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms. Presenter: Dr. John Anderson

(Source: Pharvaris)